Abstract
Aims: The primary goals of this work are to explore the potential of probiotic LAB's mucin/mucus layer thickening properties and to identify anti-obesity candidate strains that improve appropriate habitat for use with the Akkermansia group population in the future.
Methods and Results: The HT-29 cell binding, antimicrobial properties, adhesion to the mucin/mucus layer, growth in the presence of mucin, stability during in vitrogastrointestinal (GI) conditions, biofilm formation, and mucin/mucus thickness increment abilities were all assessed for artisanal LAB strains. Sixteen LAB strains out of 40 were chosen for further analysis based on their ability to withstand GI conditions. Thirteen strains maintained their vitality in the simulated intestinal fluid, whereas the majority of the strains displayed high viability in the gastric juice simulation. Furthermore, 35.2-65.4% of those 16 bacteria adhered to the mucin layer. Besides, different lactate levels were produced, and Streptococcus thermophilusUIN9 exhibited the highest biofilm development. Also, with a 50 mM lactate concentration and the presence of mucin that had been injected originally, Lacticaseibacillus casei NRRL-B 441 had the maximum amount of mucin (321.6 µg/mL).
Conclusions: Two isolates of olive bacteria from Lactiplantibacillus plantarum were chosen as the anti-obesity prototype candidates; these strains did not consume mucin sugars.
Significance and Impact of the Study: Probiotic LAB's attachment to the colonic mucosa and its ability to stimulate HT-29 cells to secrete mucus are critical mechanisms that may support the development of Akkermansia.